The UK NSC policy on Hypertrophic Cardiomyopathy (HCM) screening in teenagers
HCM is an inherited condition which, in the majority of affected people, does not limit the quality and duration of life. It is a disorder of the heart consisting of excessive growth of the muscle, which may begin before birth when the fetal heart is developing. The natural history is characterised by slow progression of symptoms but a significant incidence of sudden death.
Screening should not be offered. Pre-participation screening of athletes for HCM or other causes of sudden cardiac death should not be instituted at present.
This policy was reviewed in Dec 2008 but no significant changes were made. It is due to be considered again in 2012/13, or earlier if significant new evidence emerges.
Evidence Supporting the Policy
NSF on Coronary Heart Disease: Chapter 8 on Arrhythmias and Sudden Cardiac Death (March 2005).
The stakeholder groups will be involved when the policy is next reviewed. If you think your organisation should be added, please contact us.
Related documentsHypertrophic Cardiomyopathy Policy review (PDF document, 74KB, 03/12/10)
Notes of the UK NSC Stakeholder Meeting on Screening for Sudden Cardiac Death in Young People (PDF document, 306KB, 03/12/10)
Population screening for hypertrophic cardiomyopathy (HCM) (PDF document, 1023KB, 03/12/10)